Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
OpenProtein.AI, founded by MIT alumni Tristan Bepler and Tim Lu, has launched a no-code platform that enables researchers to design and analyze proteins using AI foundation models. The platform, which includes the PoET protein language model, is available to pharmaceutical companies and academic scientists worldwide.
Viva Biotech discussed the integration of AI and flow chemistry in drug discovery during its recent webinar, showcasing advances in automated synthesis and scalable reaction workflows.
Castle Biosciences announced it will present new data showing that its DecisionDx-Melanoma test can identify early-stage melanoma patients at greater risk of recurrence and poor outcomes. The findings will be shared at the European Congress of Dermato-Oncology and the American College of Mohs Surgery meetings.
VytlOne has launched VytlAIQ, an AI-powered platform designed to unify data, automate workflows, and provide predictive intelligence for 340B and specialty pharmacy operations.
Brado AI has completed the Centers for Medicare & Medicaid Services Health Technology Ecosystem pledge, advancing interoperability and patient-centered care through its Conversational Engagement Platform.
WCG has announced its acquisition of The Contract Network, integrating its AI technology into the ClinSphere platform to enhance contract and study start-up workflows across clinical research operations.
BayCare Health System and robotics startup Rovex have launched a pilot at Morton Plant Hospital in Clearwater, Florida, to test robotic support for hospital operations and patient transport workflows. The initial phase will study transport patterns and workflow efficiency, with no patient transport planned at this stage.
MasterControl has launched Event Summarizer, an AI feature within its Quality Excellence solution that creates instant summaries of complex quality events to speed decision-making in life sciences operations.
MyOme has appointed Sam Roosz and Dr. Ravi Thadhani to its Board of Directors, bringing expertise in healthcare technology, clinical operations, and regulatory strategy to support its AI powered whole genome healthcare platform.
Accuity has been named a winner in the Health category of the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group for its physician-governed AI platform used in hospital revenue integrity and clinical documentation.
Insilico Medicine has announced the creation of the industry's first Longevity Board to provide scientific oversight and strategic direction for AI-based aging and drug discovery research. The board will be chaired by Andrew Adams of Eli Lilly and Company.
Rad AI published a peer-reviewed study showing that radiology-specific AI models better meet radiologist expectations than general-purpose large language models when generating clinical impressions.
CerraCap Ventures has invested in Nephronomics, an AI bio precision medicine company developing data driven approaches to kidney disease research and drug discovery. The partnership aims to advance precision therapies using one of the largest renal datasets in the world.
Six NHS Trusts in north central London have signed a GBP 15.6 million contract with Sectra to consolidate their imaging systems into a single cloud environment using Sectra One Cloud, improving cybersecurity and collaboration across hospitals.
Texas Biomedical Research Institute is developing new approach methodologies that combine AI modeling, organoids, and organ-on-a-chip systems to improve drug safety and disease research.
Oracle Health has been designated as a Centers for Medicare and Medicaid Services Aligned Network and introduced a digital identity verification and check-in solution that integrates with healthcare providers’ electronic health record workflows.
Pulnovo Medical has completed a $100 million strategic financing round led by Medtronic, with participation from existing and new investors. The two companies also signed a commercial agreement to explore future marketing opportunities for Pulnovo's pulmonary artery denervation system.
Nanostics has published a peer-reviewed study validating its ClarityDX Prostate AI models for predicting aggressive prostate cancer, showing high accuracy across multiple configurations and potential to reduce unnecessary biopsies.
Mitate Zepto Technica has joined the Japan Science and Technology Agency’s Next-Generation Edge AI Semiconductor R&D Program as a social implementation partner, focusing on genome analysis acceleration through its RASEN ASIC platform.
Bracco Imaging and NYU Langone Health have signed a multi-year Master Research Agreement to advance innovation in MRI, CT, ultrasound, and AI-enabled PET/CT imaging technologies.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
